SynthesisCancer treatment reviews2023
Uncertainties and controversies in axillary management of patients with breast cancer.
Synthesis in Cancer treatment reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Clinical pathological changes in prostate cancer patients after hormonal therapy: A single-center pilot study.Biochemistry and biophysics reports · 2026Article
- Rare Breast Cancers Review.Healthcare (Basel, Switzerland) · 2024Review
- Association of Breast Cancer Subtypes and Clinicopathological Factors with Axillary Lymph Node Positivity Amongst Women with Breast Cancer in Rajasthan: An Observational Analytical Study.Indian journal of surgical oncology · 2024Article
- Identification of sentinel lymph node macrometastasis in breast cancer by deep learning based on clinicopathological characteristics.Scientific reports · 2024Article
- Article
- Management of the axilla in breast cancer patients: critical review, regional modified Delphi consensus and implementation in the Tuscan breast network.La Radiologia medica · 2024Review
- Staging of the Axilla After Neoadjuvant Chemotherapy: Which Technique is Better? The Endless Debate.Annals of surgical oncology · 2023Article
- The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus.EClinicalMedicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors.
Funding
Abstract
The aims of this Oncoplastic Breast Consortium and European Breast Cancer Research Association of Surgical Trialists initiative were to identify uncertainties and controversies in axillary management of early breast cancer and to recommend appropriate strategies to address them. By use of Delphi methods, 15 questions were prioritized by more than 250 breast surgeons, patient advocates and radiation oncologists from 60 countries. Subsequently, a global virtual consensus panel considered available data, ongoing studies and resource utilization. It agreed that research should no longer be prioritized for standardization of axillary imaging, de-escalation of axillary surgery in node-positive cancer and risk evaluation of modern surgery and radiotherapy. Instead, expert consensus recommendations for clinical practice should be based on current evidence and updated once results from ongoing studies become available. Research on de-escalation of radiotherapy and identification of the most relevant endpoints in axillary management should encompass a meta-analysis to identify knowledge gaps, followed by a Delphi process to prioritize and a consensus conference to refine recommendations for specific trial designs. Finally, treatment of residual nodal disease after surgery was recommended to be assessed in a prospective register.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.